2071 Results

People

  1. Hudis
    Hudis
  2. Norton
    Norton
  3. Zelenetz
    Zelenetz
  4. Yahalom
    Yahalom
  5. Cheung
    Cheung
  6. O'Reilly
    O'Reilly
  7. Kushner
    Kushner
  8. Perales
    Perales
  9. La Quaglia
    La Quaglia
  10. Giralt
    Giralt

Groups

  1. Department of Medicine (1047)
  2. Center for Hematologic Malignancies (589)
  3. Hematologic Malignancies, Division of (537)
  4. Survivorship Research (532)
  5. Solid Tumor Oncology Division (487)
  6. Pediatrics, Department of (383)
  7. Surgery (287)
  8. GSK Faculty (276)
  9. Breast Medicine Service (255)
  10. Tow Center for Developmental Oncology (TCDO) (240)
  1. "cyclophosphamide"
Formats
  1. Journal Article (1932)
  2. Review (52)
  3. Conference Paper (46)
  4. Editorial (11)
  5. Research Letter (11)
  6. Meeting Abstract (8)
  7. Correspondence (6)
  8. Guidelines (4)
  9. Book Section (1)
Groups
  1. Department of Medicine (1047)
  2. Center for Hematologic Malignancies (589)
  3. Hematologic Malignancies, Division of (537)
  4. Survivorship Research (532)
  5. Solid Tumor Oncology Division (487)
  6. Pediatrics, Department of (383)

More Groups

People
  1. Clifford Hudis (130)
  2. Larry Norton (104)
  3. Andrew Zelenetz (75)
  4. Joachim Yahalom (72)
  5. Nai-Kong Cheung (71)
  6. Richard O'Reilly (67)

More People

Years
  1. 2025 (45)
  2. 2024 (86)
  3. 2023 (56)
  4. 2022 (44)
  5. 2021 (23)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (155)
  2. Cancer (109)
  3. Blood (81)
  4. Leukemia and Lymphoma (50)
  5. Biology of Blood and Marrow Transplantation (49)
  6. Bone Marrow Transplantation (48)

More Publications

Publishers
  1. Elsevier Inc. (345)
  2. American Society of Clinical Oncology (163)
  3. Wiley Blackwell (150)
  4. Springer (147)
  5. American Society of Hematology (113)
  6. Lippincott Williams & Wilkins (112)

More Publishers

Results (2071)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features
    Correspondence

    Zibara, V.; Sen, F.; Scordo, M.; Falchi, L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease
    Journal Article

    Burgos da Silva, M.; Ponce, D. M.; Dai, A.; Devlin, S. M.; Gomes, A. L. C.; Moore, G.; Slingerland, J.; Shouval, R.; Armijo, G. K.; DeWolf, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b–2, open-label study
    Journal Article

    Martin, T.; Lin, Y.; Agha, M.; Cohen, A. D.; Htut, M.; Stewart, A. K.; Hari, P.; Berdeja, J. G.; Usmani, S. Z.; Yeh, T. M.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
    Journal Article

    Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • Oncologic emergencies and urgencies: A comprehensive review
    Review

    Gould Rothberg, B. E.; Quest, T. E.; Yeung, S. C. J.; Pelosof, L. C.; Gerber, D. E.; Seltzer, J. A.; Bischof, J. J.; Thomas, C. R. Jr; Akhter, N.; Mamtani, M.; more...
    CA - A Cancer Journal for Clinicians (2022)

    Fulltext@MSK | Save
  • Neoadjuvant chemotherapy for breast cancer in the elderly: Are we accomplishing our treatment goals?
    Journal Article

    Williams, A. D.; Dang, C. T.; Sevilimedu, V.; Morrow, M.; Barrio, A. V.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to synergic activity
    Review

    Berretta, M.; Dal Lago, L.; Tinazzi, M.; Ronchi, A.; La Rocca, G.; Montella, L.; Di Francia, R.; Facchini, B. A.; Bignucolo, A.; Montopoli, M.
    Cancers (2022)

    Fulltext@MSK | Save
  • Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis
    Journal Article

    Saliba, R. M.; Alousi, A. M.; Pidala, J.; Arora, M.; Spellman, S. R.; Hemmer, M. T.; Wang, T.; Abboud, C.; Ahmed, S.; Antin, J. H.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas
    Journal Article

    Riedell, P. A.; Hwang, W. T.; Nastoupil, L. J.; Pennisi, M.; McGuirk, J. P.; Maziarz, R. T.; Bachanova, V.; Oluwole, O. O.; Brower, J.; Flores, O. A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: A case for response-adapted approach
    Journal Article

    Lahoud, O. B.; Landau, H.; Nguyen, J.; Devlin, S.; Lendvai, N.; Weltz, J.; Ayorinde, T.; Chung, D. J.; Lesokhin, A. M.; Kewalramani, T.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save